Anca Nastase1, Audrey Lupo2, Victoria Laszlo1, Diane Damotte2, Simona Dima1, Emelyne Canny2, Marco Alifano2, Irinel Popescu1, Walter Klepetko3, Madalina Grigoroiu4. 1. Center of Digestive Diseases and Liver Transplantation, Fundeni Clinical Institute, Bucharest, Romania. 2. Department of Pathology, Hôpital Cochin, AP-HP, Université de Paris, Paris, France. 3. Department of Thoracic Surgery, Vienna General Hospital, Vienna, Austria. 4. Center of Digestive Diseases and Liver Transplantation, Fundeni Clinical Institute, Bucharest, Romania madalinalidia@yahoo.com.
Abstract
BACKGROUND/AIM: Patients with stage IIIA (N2) non-small cell lung cancer (NSCLC) with no progression after induction chemotherapy are usually selected for surgery. Nowadays, response to chemotherapy is not predictable. We aimed to identify genomic predictive markers for response to induction chemotherapy in stage IIIA (N2) NSCLC patients. PATIENTS AND METHODS: Whole-exome sequencing (WES) was performed on samples from 11 patients with no response after induction chemotherapy and 6 patients with documented pathological response, admitted to the Hotel Dieu Hospital, Paris or Allegemeines Krakenhaus University, Vienna. RESULTS: A higher alternative allele frequency was found on SENP5, rs63736860, rs1602 and NCBP2, rs553783 in the non-responder group, and on RGP1, rs1570248, SLFN12L, rs2304968, rs9905892, and GBA2, rs3833700 in the responder group. CONCLUSION: These polymorphisms contribute to inter-individual sensibility to chemotherapy response. Interrogation of these genetic variations may have potential applicability when deciding the treatment strategy for patients with stage III NSCLC (N2). Copyright
BACKGROUND/AIM: Patients with stage IIIA (N2) non-small cell lung cancer (NSCLC) with no progression after induction chemotherapy are usually selected for surgery. Nowadays, response to chemotherapy is not predictable. We aimed to identify genomic predictive markers for response to induction chemotherapy in stage IIIA (N2) NSCLCpatients. PATIENTS AND METHODS: Whole-exome sequencing (WES) was performed on samples from 11 patients with no response after induction chemotherapy and 6 patients with documented pathological response, admitted to the Hotel Dieu Hospital, Paris or Allegemeines Krakenhaus University, Vienna. RESULTS: A higher alternative allele frequency was found on SENP5, rs63736860, rs1602 and NCBP2, rs553783 in the non-responder group, and on RGP1, rs1570248, SLFN12L, rs2304968, rs9905892, and GBA2, rs3833700 in the responder group. CONCLUSION: These polymorphisms contribute to inter-individual sensibility to chemotherapy response. Interrogation of these genetic variations may have potential applicability when deciding the treatment strategy for patients with stage III NSCLC (N2). Copyright
Authors: Rafael Santana-Davila; Aniko Szabo; Carlos Arce-Lara; Christina D Williams; Michael J Kelley; Jeff Whittle Journal: J Thorac Oncol Date: 2014-05 Impact factor: 15.609
Authors: Ludmil B Alexandrov; Serena Nik-Zainal; David C Wedge; Peter J Campbell; Michael R Stratton Journal: Cell Rep Date: 2013-01-10 Impact factor: 9.423
Authors: J Ferlay; M Colombet; I Soerjomataram; C Mathers; D M Parkin; M Piñeros; A Znaor; F Bray Journal: Int J Cancer Date: 2018-12-06 Impact factor: 7.396